Skip to main content
NCBI home page
Archives of Disease in Childhood. Fetal and Neonatal Edition logoLink to Archives of Disease in Childhood. Fetal and Neonatal Edition
. 2004 Mar;89(2):F96–F100. doi: 10.1136/adc.2003.028696

Postnatal steroid treatment and brain development

O Baud
PMCID: PMC1756046  PMID: 14977889

Full Text

The Full Text of this article is available as a PDF (194.1 KB).

Figure 1 .

Figure 1

Open in a new tab

Main benefits of postnatal steroid treatment in preterm infants according to the regimen used.16–18 E, Early regimen (< 96 h of life); M, moderately early regimen (7–14 days of life); D, delayed regimen (> 3 weeks of life); CLD, chronic lung disease; FEd28, failure to extubate at day 28; O2, oxygen at home.

Figure 2 .

Figure 2

Open in a new tab

Main adverse effects of postnatal steroid treatment in preterm infants according to the regimen used.16–18 E, Early regimen (< 96 h of life); M, moderately early regimen (7–14 days of life); D, delayed regimen (> 3 weeks of life); HG, hyperglycaemia; SI, secondary infection; HT, arterial hypertension; IB, intestinal bleeding; CP, cerebral palsy.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ajayi-Obe M., Saeed N., Cowan F. M., Rutherford M. A., Edwards A. D. Reduced development of cerebral cortex in extremely preterm infants. Lancet. 2000 Sep 30;356(9236):1162–1163. doi: 10.1016/s0140-6736(00)02761-6. [DOI] [PubMed] [Google Scholar]
  2. André P., Thébaud B., Odièvre M. H., Razafimahefa H., Zupan V., Dehan M., Lacaze-Masmonteil T. Methylprednisolone, an alternative to dexamethasone in very premature infants at risk of chronic lung disease. Intensive Care Med. 2000 Oct;26(10):1496–1500. doi: 10.1007/s001340000588. [DOI] [PubMed] [Google Scholar]
  3. Arquié Cyrille, Leroux Philippe, Bodenant Corinne, Laquerrière Annie, Marpeau Loïc, Marret Stéphane. Glucocorticoid treatment in an ischaemic-like excitotoxic model of periventricular leucomalacia in mice. BJOG. 2002 Sep;109(9):989–996. [PubMed] [Google Scholar]
  4. Avery G. B., Fletcher A. B., Kaplan M., Brudno D. S. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics. 1985 Jan;75(1):106–111. [PubMed] [Google Scholar]
  5. Back Stephen A., Han Byung Hee, Luo Ning Ling, Chricton Charlene A., Xanthoudakis Steve, Tam John, Arvin Kara L., Holtzman David M. Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci. 2002 Jan 15;22(2):455–463. doi: 10.1523/JNEUROSCI.22-02-00455.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Baden M., Bauer C. R., Colle E., Klein G., Taeusch H. W., Jr, Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics. 1972 Oct;50(4):526–534. [PubMed] [Google Scholar]
  7. Barrington K. J. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr. 2001 Feb 27;1:1–1. doi: 10.1186/1471-2431-1-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Baud O., Foix-L'Helias L., Kaminski M., Audibert F., Jarreau P. H., Papiernik E., Huon C., Lepercq J., Dehan M., Lacaze-Masmonteil T. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med. 1999 Oct 14;341(16):1190–1196. doi: 10.1056/NEJM199910143411604. [DOI] [PubMed] [Google Scholar]
  9. Baud O. Is perinatal dexamethasone treatment safe in preterm infants? Dev Med Child Neurol Suppl. 2001 Mar;86:23–25. doi: 10.1111/j.1469-8749.2001.tb04143.x. [DOI] [PubMed] [Google Scholar]
  10. Baud O., Laudenbach V., Evrard P., Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res. 2001 Dec;50(6):706–711. doi: 10.1203/00006450-200112000-00013. [DOI] [PubMed] [Google Scholar]
  11. Benesová O., Pavlík A. Perinatal treatment with glucocorticoids and the risk of maldevelopment of the brain. Neuropharmacology. 1989 Jan;28(1):89–97. doi: 10.1016/0028-3908(89)90073-7. [DOI] [PubMed] [Google Scholar]
  12. Bhuta T., Ohlsson A. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 1998 Jul;79(1):F26–F33. doi: 10.1136/fn.79.1.f26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Bos A. F., Martijn A., van Asperen R. M., Hadders-Algra M., Okken A., Prechtl H. F. Qualitative assessment of general movements in high-risk preterm infants with chronic lung disease requiring dexamethasone therapy. J Pediatr. 1998 Feb;132(2):300–306. doi: 10.1016/s0022-3476(98)70449-4. [DOI] [PubMed] [Google Scholar]
  14. Dammann O., Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res. 1997 Jul;42(1):1–8. doi: 10.1203/00006450-199707000-00001. [DOI] [PubMed] [Google Scholar]
  15. Flavin M. P. Influence of dexamethasone on neurotoxicity caused by oxygen and glucose deprivation in vitro. Exp Neurol. 1996 May;139(1):34–38. doi: 10.1006/exnr.1996.0078. [DOI] [PubMed] [Google Scholar]
  16. HADDAD H. M., HSIA D. Y. Y., GELLIS S. S. Studies on respiratory rate in the newborn; its use in the evaluation of respiratory distress in infants of diabetic mothers. Pediatrics. 1956 Feb;17(2):204–213. [PubMed] [Google Scholar]
  17. Halliday H. L. Clinical trials of postnatal corticosteroids: inhaled and systemic. Biol Neonate. 1999 Jun;76 (Suppl 1):29–40. doi: 10.1159/000047044. [DOI] [PubMed] [Google Scholar]
  18. Halliday H. L., Ehrenkranz R. A., Doyle L. W. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001145–CD001145. doi: 10.1002/14651858.CD001145. [DOI] [PubMed] [Google Scholar]
  19. Halliday H. L., Ehrenkranz R. A., Doyle L. W. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001146–CD001146. doi: 10.1002/14651858.CD001146. [DOI] [PubMed] [Google Scholar]
  20. Halliday H. L., Ehrenkranz R. A., Doyle L. W. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001144–CD001144. doi: 10.1002/14651858.CD001144. [DOI] [PubMed] [Google Scholar]
  21. Halliday Henry L. Early postnatal dexamethasone and cerebral palsy. Pediatrics. 2002 Jun;109(6):1168–1169. doi: 10.1542/peds.109.6.1168. [DOI] [PubMed] [Google Scholar]
  22. Howard E. Reductions in size and total DNA of cerebrum and cerebellum in adult mice after corticosterone treatment in infancy. Exp Neurol. 1968 Oct;22(2):191–208. doi: 10.1016/0014-4886(68)90051-4. [DOI] [PubMed] [Google Scholar]
  23. Inder T. E., Huppi P. S., Warfield S., Kikinis R., Zientara G. P., Barnes P. D., Jolesz F., Volpe J. J. Periventricular white matter injury in the premature infant is followed by reduced cerebral cortical gray matter volume at term. Ann Neurol. 1999 Nov;46(5):755–760. doi: 10.1002/1531-8249(199911)46:5<755::aid-ana11>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  24. Jobe A. H., Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev. 1998 Nov;53(1):81–94. doi: 10.1016/s0378-3782(98)00045-0. [DOI] [PubMed] [Google Scholar]
  25. Kauffman K. S., Seidler F. J., Slotkin T. A. Prenatal dexamethasone exposure causes loss of neonatal hypoxia tolerance: cellular mechanisms. Pediatr Res. 1994 May;35(5):515–522. [PubMed] [Google Scholar]
  26. Kuban K. C., Leviton A. Cerebral palsy. N Engl J Med. 1994 Jan 20;330(3):188–195. doi: 10.1056/NEJM199401203300308. [DOI] [PubMed] [Google Scholar]
  27. Larroque B., Samain H., Groupe Epipage Etude Epipage: mortalité des enfants grands prématurés et état d'avancement du suivi. J Gynecol Obstet Biol Reprod (Paris) 2001 Oct;30(6 Suppl):S33–S41. [PubMed] [Google Scholar]
  28. Lee S. K., McMillan D. D., Ohlsson A., Pendray M., Synnes A., Whyte R., Chien L. Y., Sale J. Variations in practice and outcomes in the Canadian NICU network: 1996-1997. Pediatrics. 2000 Nov;106(5):1070–1079. doi: 10.1542/peds.106.5.1070. [DOI] [PubMed] [Google Scholar]
  29. Liggins G. C., Howie R. N. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972 Oct;50(4):515–525. [PubMed] [Google Scholar]
  30. Mammel M. C., Green T. P., Johnson D. E., Thompson T. R. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet. 1983 Jun 18;1(8338):1356–1358. doi: 10.1016/s0140-6736(83)92139-6. [DOI] [PubMed] [Google Scholar]
  31. Marret S., Gressens P., Evrard P. Arrest of neuronal migration by excitatory amino acids in hamster developing brain. Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15463–15468. doi: 10.1073/pnas.93.26.15463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. McGowan J. E., Sysyn G., Petersson K. H., Sadowska G. B., Mishra O. P., Delivoria-Papadopoulos M., Stonestreet B. S. Effect of dexamethasone treatment on maturational changes in the NMDA receptor in sheep brain. J Neurosci. 2000 Oct 1;20(19):7424–7429. doi: 10.1523/JNEUROSCI.20-19-07424.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Modi N., Lewis H., Al-Naqeeb N., Ajayi-Obe M., Doré C. J., Rutherford M. The effects of repeated antenatal glucocorticoid therapy on the developing brain. Pediatr Res. 2001 Nov;50(5):581–585. doi: 10.1203/00006450-200111000-00008. [DOI] [PubMed] [Google Scholar]
  34. Murphy B. P., Inder T. E., Huppi P. S., Warfield S., Zientara G. P., Kikinis R., Jolesz F. A., Volpe J. J. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics. 2001 Feb;107(2):217–221. doi: 10.1542/peds.107.2.217. [DOI] [PubMed] [Google Scholar]
  35. Nelson K. B., Dambrosia J. M., Grether J. K., Phillips T. M. Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann Neurol. 1998 Oct;44(4):665–675. doi: 10.1002/ana.410440413. [DOI] [PubMed] [Google Scholar]
  36. O'Shea T. M., Kothadia J. M., Klinepeter K. L., Goldstein D. J., Jackson B. G., Weaver R. G., 3rd, Dillard R. G. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999 Jul;104(1 Pt 1):15–21. doi: 10.1542/peds.104.1.15. [DOI] [PubMed] [Google Scholar]
  37. Prodanov D., Mantchev G., Iliev A., Traykov V., Yakimova K., Kaneva R., Krushkov I. Effects of dexamethasone in rat neonatal model of axotomy-induced motoneuronal cell death. Arch Physiol Biochem. 1998 Dec;106(5):355–361. doi: 10.1076/apab.106.5.355.4361. [DOI] [PubMed] [Google Scholar]
  38. Rennie J. M., Wheater M., Cole T. J. Antenatal steroid administration is associated with an improved chance of intact survival in preterm infants. Eur J Pediatr. 1996 Jul;155(7):576–579. doi: 10.1007/BF01957908. [DOI] [PubMed] [Google Scholar]
  39. Riva M. A., Fumagalli F., Racagni G. Opposite regulation of basic fibroblast growth factor and nerve growth factor gene expression in rat cortical astrocytes following dexamethasone treatment. J Neurochem. 1995 Jun;64(6):2526–2533. doi: 10.1046/j.1471-4159.1995.64062526.x. [DOI] [PubMed] [Google Scholar]
  40. Romagnoli C., Zecca E., Luciano R., Torrioli G., Tortorolo G. A three year follow up of preterm infants after moderately early treatment with dexamethasone. Arch Dis Child Fetal Neonatal Ed. 2002 Jul;87(1):F55–F58. doi: 10.1136/fn.87.1.F55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Saliba E., Marret S. Cerebral white matter damage in the preterm infant: pathophysiology and risk factors. Semin Neonatol. 2001 Apr;6(2):121–133. doi: 10.1053/siny.2001.0043. [DOI] [PubMed] [Google Scholar]
  42. Schwab M., Antonow-Schlorke I., Kühn B., Müller T., Schubert H., Walter B., Sliwka U., Nathanielsz P. W. Effect of antenatal betamethasone treatment on microtubule-associated proteins MAP1B and MAP2 in fetal sheep. J Physiol. 2001 Feb 1;530(Pt 3):497–506. doi: 10.1111/j.1469-7793.2001.0497k.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Shah S. S., Ohlsson A., Halliday H., Shah V. S. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev. 2003;(1):CD002058–CD002058. doi: 10.1002/14651858.CD002058. [DOI] [PubMed] [Google Scholar]
  44. Shi B., Rabin S. J., Brandoli C., Mocchetti I. Dexamethasone induces hypertrophy of developing medial septum cholinergic neurons: potential role of nerve growth factor. J Neurosci. 1998 Nov 15;18(22):9326–9334. doi: 10.1523/JNEUROSCI.18-22-09326.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Shinwell E. S., Karplus M., Reich D., Weintraub Z., Blazer S., Bader D., Yurman S., Dolfin T., Kogan A., Dollberg S. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 2000 Nov;83(3):F177–F181. doi: 10.1136/fn.83.3.F177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Stark A. R., Carlo W. A., Tyson J. E., Papile L. A., Wright L. L., Shankaran S., Donovan E. F., Oh W., Bauer C. R., Saha S. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 2001 Jan 11;344(2):95–101. doi: 10.1056/NEJM200101113440203. [DOI] [PubMed] [Google Scholar]
  47. Stone D. J., Walsh J. P., Sebro R., Stevens R., Pantazopolous H., Benes F. M. Effects of pre- and postnatal corticosterone exposure on the rat hippocampal GABA system. Hippocampus. 2001;11(5):492–507. doi: 10.1002/hipo.1066. [DOI] [PubMed] [Google Scholar]
  48. Tahraoui S. L., Marret S., Bodénant C., Leroux P., Dommergues M. A., Evrard P., Gressens P. Central role of microglia in neonatal excitotoxic lesions of the murine periventricular white matter. Brain Pathol. 2001 Jan;11(1):56–71. doi: 10.1111/j.1750-3639.2001.tb00381.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Tombaugh G. C., Yang S. H., Swanson R. A., Sapolsky R. M. Glucocorticoids exacerbate hypoxic and hypoglycemic hippocampal injury in vitro: biochemical correlates and a role for astrocytes. J Neurochem. 1992 Jul;59(1):137–146. doi: 10.1111/j.1471-4159.1992.tb08884.x. [DOI] [PubMed] [Google Scholar]
  50. Tsubota S., Adachi N., Chen J., Yorozuya T., Nagaro T., Arai T. Dexamethasone changes brain monoamine metabolism and aggravates ischemic neuronal damage in rats. Anesthesiology. 1999 Feb;90(2):515–523. doi: 10.1097/00000542-199902000-00028. [DOI] [PubMed] [Google Scholar]
  51. Tuor U. I., Chumas P. D., Del Bigio M. R. Prevention of hypoxic-ischemic damage with dexamethasone is dependent on age and not influenced by fasting. Exp Neurol. 1995 Mar;132(1):116–122. doi: 10.1016/0014-4886(95)90065-9. [DOI] [PubMed] [Google Scholar]
  52. Volpe J. J. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr Res. 2001 Nov;50(5):553–562. doi: 10.1203/00006450-200111000-00003. [DOI] [PubMed] [Google Scholar]
  53. Watterberg K. L., Gerdes J. S., Gifford K. L., Lin H. M. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics. 1999 Dec;104(6):1258–1263. doi: 10.1542/peds.104.6.1258. [DOI] [PubMed] [Google Scholar]
  54. Weichsel M. E., Jr The therapeutic use of glucocorticoid hormones in the perinatal period: potential neurological hazards. Ann Neurol. 1977 Nov;2(5):364–366. doi: 10.1002/ana.410020503. [DOI] [PubMed] [Google Scholar]
  55. Yoon B. H., Romero R., Yang S. H., Jun J. K., Kim I. O., Choi J. H., Syn H. C. Interleukin-6 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia. Am J Obstet Gynecol. 1996 May;174(5):1433–1440. doi: 10.1016/s0002-9378(96)70585-9. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood Fetal and Neonatal Edition are provided here courtesy of BMJ Publishing Group

RESOURCES